ArticleScientific reports2026
High prevalence of bancroftian filariasis and comorbidities in the eastern coalfield regions of West Bengal, India following COVID-19 disruption.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Lymphatic filariasis (LF) is one of the most debilitating parasitic diseases worldwide, casting a shadow of socio-economic stigma over the affected underprivileged communities. The present study is a maiden investigation depicting LF prevalence in the previously unexplored remote eastern coalfield districts of West Bengal state, India during and after COVID-19 pandemic. A community-based cross-sectional survey (August 2021–March 2024) was conducted in four LF-endemic districts of West Bengal. Symptomatic cases were graded clinically, and asymptomatic infections confirmed by filaria-specific IgG/IgM and nocturnal microfilariae (mf) detection. Comorbidities were systematically recorded. Of 3705 individuals (50.7% females and 49.3% males) screened, the overall LF prevalence was 16.65% (95% CI:15.45% -17.85%, 617 individuals). Asymptomatic mf + ICT-positive cases accounted for 10.63% (95% CI, 9.64–11.62; n = 394), while 6.02% (95% CI, 5.30–6.82; n = 223) were symptomatic. Among the symptomatic cases, 144 had circulating mf, filaria-specific IgG/IgM (ICT positive) and clinical symptoms of lymphedema, most commonly Grade II (34.79%) and Grade III (43.48%). Chronic mf-negative lymphedema was observed in 2.13% (n = 79). Active LF prevalence, defined by mf and ICT positivity, was 14.52% (95% CI, 13.4–15.7; n = 538). Acute dermato-lymphangio-adenitis (ADLA) among the clinical categories was ranged between 8.71% and 39.79%. LF prevalence was higher in the rural areas, while hypertension, diabetes, and fungal infections as major comorbidities. The eastern coalfield region of West Bengal state presents heightened prevalence of severe chronic lymphedema and a marginal prevalence of new LF cases possibly due to interruption of mass drug administration in this neglected remote areas and poor morbidity management during COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.